StockNews.com Downgrades Mesoblast (NASDAQ:MESO) to Sell

Mesoblast (NASDAQ:MESO) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Mesoblast in a report on Friday, January 12th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $13.67.

Mesoblast Price Performance

MESO opened at $7.17 on Wednesday. Mesoblast has a fifty-two week low of $1.61 and a fifty-two week high of $10.24. The firm has a market capitalization of $818.66 million, a PE ratio of -6.40 and a beta of 3.45. The company’s 50-day moving average is $4.75 and its 200 day moving average is $3.05.

Institutional Trading of Mesoblast

A number of institutional investors and hedge funds have recently modified their holdings of the business. Chase Investment Counsel Corp bought a new stake in shares of Mesoblast in the 1st quarter worth approximately $298,000. Prosperity Wealth Management Inc. bought a new stake in shares of Mesoblast in the third quarter valued at $79,000. Finally, Lazari Capital Management Inc. lifted its position in shares of Mesoblast by 9.3% during the 3rd quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company’s stock valued at $116,000 after buying an additional 8,000 shares during the last quarter. 1.43% of the stock is owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.